35.27
price down icon1.18%   -0.42
after-market  After Hours:  35.27 
loading
Celldex Therapeutics Inc. stock is currently priced at $35.27, with a 24-hour trading volume of 1.51M. It has seen a -1.18% decreased in the last 24 hours and a -6.37% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $35.27 pivot point. If it approaches the $36.14 resistance level, significant changes may occur.
Previous Close:
$35.69
Open:
$35.88
24h Volume:
1.51M
Market Cap:
$2.32B
Revenue:
$6.07M
Net Income/Loss:
$-144.88M
P/E Ratio:
-13.36
EPS:
-2.64
Net Cash Flow:
$-120.94M
1W Performance:
+1.73%
1M Performance:
-6.37%
6M Performance:
-6.72%
1Y Performance:
-4.55%
1D Range:
Value
$34.78
$36.00
52W Range:
Value
$22.11
$53.18

Celldex Therapeutics Inc. Stock (CLDX) Company Profile

Name
Name
Celldex Therapeutics Inc.
Name
Phone
908-200-7500
Name
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton
Name
Employee
192
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
CLDX's Discussions on Twitter

Celldex Therapeutics Inc. Stock (CLDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-23 Initiated TD Cowen Outperform
Nov-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Aug-22-23 Initiated Wells Fargo Underweight
Sep-17-21 Initiated Jefferies Buy
Sep-10-21 Initiated SVB Leerink Outperform
Jul-22-21 Initiated Guggenheim Buy
Feb-21-20 Initiated Cantor Fitzgerald Overweight
Aug-01-17 Resumed H.C. Wainwright Buy
Nov-07-16 Initiated Aegis Capital Buy
Mar-08-16 Downgrade Jefferies Buy → Hold
Mar-07-16 Downgrade Guggenheim Buy → Neutral
Mar-07-16 Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16 Downgrade Wedbush Outperform → Neutral
Mar-01-16 Initiated H.C. Wainwright Buy
Aug-11-15 Reiterated Brean Capital Buy
Aug-11-15 Reiterated Oppenheimer Outperform
Aug-11-15 Reiterated ROTH Capital Buy
Jun-02-15 Reiterated WBB Securities Strong Buy
Nov-17-14 Reiterated ROTH Capital Buy
Mar-04-14 Reiterated Oppenheimer Outperform
Jul-08-13 Reiterated Cantor Fitzgerald Buy
Mar-08-13 Reiterated Cantor Fitzgerald Buy
Feb-26-13 Reiterated Oppenheimer Outperform
Jan-10-13 Reiterated Cantor Fitzgerald Buy
Oct-02-12 Reiterated Oppenheimer Outperform
Sep-14-12 Reiterated Cantor Fitzgerald Buy
View All

Celldex Therapeutics Inc. Stock (CLDX) Financials Data

Celldex Therapeutics Inc. (CLDX) Revenue 2024

CLDX reported a revenue (TTM) of $6.07 million for the quarter ending March 31, 2024, a +92.76% rise year-over-year.
loading

Celldex Therapeutics Inc. (CLDX) Net Income 2024

CLDX net income (TTM) was -$144.88 million for the quarter ending March 31, 2024, a -22.12% decrease year-over-year.
loading

Celldex Therapeutics Inc. (CLDX) Cash Flow 2024

CLDX recorded a free cash flow (TTM) of -$120.94 million for the quarter ending March 31, 2024, a -10.34% decrease year-over-year.
loading

Celldex Therapeutics Inc. (CLDX) Earnings per Share 2024

CLDX earnings per share (TTM) was -$2.86 for the quarter ending March 31, 2024, a -13.49% decline year-over-year.
loading
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
$83.78
price down icon 1.10%
$156.11
price up icon 0.37%
$26.03
price up icon 0.58%
$84.64
price down icon 1.44%
$165.70
price up icon 5.27%
$394.47
price up icon 1.70%
Cap:     |  Volume (24h):